000148107 001__ 148107 000148107 005__ 20250114155432.0 000148107 0247_ $$2doi$$a10.3390/jcm10081568 000148107 0248_ $$2sideral$$a125983 000148107 037__ $$aART-2021-125983 000148107 041__ $$aeng 000148107 100__ $$0(orcid)0000-0002-1275-2600$$aSantander Ballestín, Sonia$$uUniversidad de Zaragoza 000148107 245__ $$aHepatitis C: A Pharmacological Therapeutic Update 000148107 260__ $$c2021 000148107 5060_ $$aAccess copy available to the general public$$fUnrestricted 000148107 5203_ $$a(1) Background: Hepatitis C is a high-prevalence disease, representing a global impact health problem. Lately, many changes have been made in treatment guidelines because of the commercialization of second-generation direct-acting antivirals due to their high effectiveness, few side effects and pangenotypic action. We address the pharmacological possibilities available and compare them with the current recommendations of the World Health Organization (WHO). (2) Methods: The search for articles was made through the PubMed database using different search strategies and we consulted technical data sheets of the treatments that have been included in the study. (3) Results: Combinations of “glecaprevir/pibrentasvir”, “sofosbuvir/velpatasvir” and “sofosbuvir/velpatasvir/voxilaprevir” have been recently incorporated. Phase II studies have shown that they are safe and effective therapies with very comfortable posologies and easy therapeutic adherence; furthermore, they suppose shorter treatment duration. Subsequently, phase III studies have shown they were effective for previously treated or compensated cirrhotic patients that previously had more complex treatment regimens. (4) Conclusions: These results suppose a simplification in Hepatitis C therapeutic approach, and open new study possibilities. 000148107 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000148107 590__ $$a4.964$$b2021 000148107 591__ $$aMEDICINE, GENERAL & INTERNAL$$b55 / 172 = 0.32$$c2021$$dQ2$$eT1 000148107 592__ $$a1.04$$b2021 000148107 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1 000148107 594__ $$a4.4$$b2021 000148107 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000148107 700__ $$aGómez Martín, David 000148107 700__ $$0(orcid)0000-0003-4672-8083$$aLorente Pérez, Sara$$uUniversidad de Zaragoza 000148107 700__ $$0(orcid)0000-0003-4071-1467$$aLuesma Bartolomé, María José$$uUniversidad de Zaragoza 000148107 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000148107 7102_ $$11003$$2027$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Anatom.Embriol.Humana 000148107 7102_ $$11012$$2315$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Farmacología 000148107 773__ $$g10, 8 (2021), 1568$$pJ. clin.med.$$tJournal of Clinical Medicine$$x2077-0383 000148107 8564_ $$s1939151$$uhttps://zaguan.unizar.es/record/148107/files/texto_completo.pdf$$yVersión publicada 000148107 8564_ $$s2731440$$uhttps://zaguan.unizar.es/record/148107/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000148107 909CO $$ooai:zaguan.unizar.es:148107$$particulos$$pdriver 000148107 951__ $$a2025-01-13-14:27:56 000148107 980__ $$aARTICLE